<DOC>
	<DOC>NCT00647764</DOC>
	<brief_summary>Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.</brief_summary>
	<brief_title>Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Solid tumors or lymphoid malignancies refractory to standard therapy measurable disease recovery to Grade &lt; 1 toxicity due to prior adverse event or chemotherapy no chemotherapy within 4 weeks of entering study Age &gt; 18 years Karnofsy &gt;= 60% Life expectancy &gt; 3 months normal or adequate organ and marrow function receiving other investigational agents brain metastases uncontrolled medical illness HIV+ receiving combination antiretroviral therapy significant GI disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>